ABT-072 clinical trials
Also written ABT-072.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses ABT-072 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABT-072
- 7
Studies by the year they started
7 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ABT-072 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01074008Written as ABT-072
- A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01221298Written as ABT-072
- A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 StudiesCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00872196Written as ABT-072
- A Study of Single Doses of ABT-072 in Japanese Healthy Male AdultsCompletedPhase 1AbbottNCT01081483Written as ABT-072
- Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule FormulationCompletedPhase 1AbbottNCT00947440Written as ABT-072
- Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072CompletedPhase 1AbbottNCT00982826Written as ABT-072
- A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected AdultsCompletedPhase 1AbbottNCT00752687Written as ABT-072